Radiation oncology firm Accuray has garnered U.S. Food and Drug Administration (FDA) 510(k) clearance for its ClearRT helical kilovoltage CT (kVCT) imaging technology.
Integrated into the company's Radixact radiation therapy platform, ClearRT is designed to produce CT images with diagnostic-like quality, according to the vendor. It can provide helical fan-beam imaging at both kV and megavoltage (mV) wavelengths, supporting imaging requirements for patient setup and registration, Accuray said.
ClearCT is expected to be commercially available for Radixact in the spring of 2021, according to the vendor.
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
